Currently, there are 37.17M common shares owned by the public and among those 37.12M shares have been available to trade.
The company’s stock has a 5-day price change of 5.81% and 12.12% over the past three months. APGE shares are trading 83.14% year to date (YTD), with the 12-month market performance up to 114.10% higher. It has a 12-month low price of $14.19 and touched a high of $72.29 over the same period. APGE has an average intraday trading volume of 435.03K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 12.65%, 14.76%, and 22.01% respectively.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Institutional ownership of Apogee Therapeutics Inc. (NASDAQ: APGE) shares accounts for 76.97% of the company’s 37.17M shares outstanding.
It has a market capitalization of $2.99B and a beta (3y monthly) value of 2.82. The earnings-per-share (ttm) stands at -$2.28. Price movements for the stock have been influenced by the stock’s volatility, which stands at 4.16% over the week and 5.72% over the month.
Analysts forecast that Apogee Therapeutics Inc. (APGE) will achieve an EPS of -0.77 for the current quarter, -0.91 for the next quarter and -3.6 for current fiscal year. The lowest estimate earnings-per-share for the quarter is -1.04 while analysts give the company a high EPS estimate of -1.04. Comparatively, EPS for the current quarter was -0.51 a year ago. Earnings per share for the fiscal year are expected to increase by 16.91%, and -26.63% over the next financial year.
Looking at the support for the APGE, a number of firms have released research notes about the stock. BofA Securities stated their Buy rating for the stock in a research note on May 10, 2024, with the firm’s price target at $80. BTIG Research coverage for the Apogee Therapeutics Inc. (APGE) stock in a research note released on December 20, 2023 offered a Buy rating with a price target of $43. Stifel on their part issued Buy rating on August 08, 2023.
